Lexaria Bioscience Corp. reported that its Phase 1b GLP‑1‑H24‑4 study met its primary safety and tolerability endpoint, showing a 48 % reduction in overall adverse events and a 55 % reduction in gastrointestinal events compared with the oral GLP‑1 drug Rybelsus®.
The 12‑week chronic study was conducted in Australia and evaluated five DehydraTECH‑processed arms, including DehydraTECH‑semaglutide, DehydraTECH‑tirzepatide, a DehydraTECH‑CBD/semaglutide combination, a DehydraTECH‑CBD arm, and a DehydraTECH‑CBD/semaglutide/tirzepatide combination. The study design and duration were chosen to capture long‑term tolerability, a key driver of patient adherence in the GLP‑1 market.
Lexaria also raised $7.5 million in gross proceeds through two equity transactions, providing a runway through 2026. The company extended its Material Transfer Agreement with PharmaCo through April 30, 2026, and indicated that the data could accelerate a licensing conversion. The financing and partnership extension give Lexaria the resources and strategic partnership needed to move the DehydraTECH platform into later‑stage development.
The results are significant because high discontinuation rates—often driven by gastrointestinal side effects—limit the commercial potential of oral GLP‑1 therapies. By demonstrating a roughly 50 % reduction in side effects, Lexaria’s platform could improve patient adherence and capture a larger share of the projected $100 billion‑plus GLP‑1 market.
Investors reacted to the announcement with a 7.7 % decline in Lexaria’s share price, largely driven by the recent equity offering that diluted existing shareholders. The clinical data itself was positive, but the market focused on the dilution effect of the $3.5 million at‑market offering that closed on December 16.
CEO Richard Christopher said the company was “extremely pleased” with the primary endpoint success and emphasized that the data would be shared with PharmaCo to potentially accelerate a licensing conversion. He also highlighted the importance of the recent financing in supporting the company’s 2026 development plans.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.